KIT and gastrointestinal stromal tumor: Several additional novel KIT inhibitors including bezuclastinib (28), NB003 (29), and THE-630 (48, 49) have recently entered early clinical development for advanced GIST, and their safety profiles and efficacy remain to be seen.